US 12,447,159 B2
3β-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of Cannabinoids-Related Disorders
Pier Vincenzo Piazza, Bordeaux (FR); Sandy Fabre, Bordeaux (FR); Mathilde Metna, Bordeaux (FR); Stephanie Monlezun, Bordeaux (FR); Arnau Busquet-Garcia, Bordeaux (FR); Daniela Cota, Bordeaux (FR); Giovanni Marsicano, Bordeaux (FR); Jean-Michel Revest, Bordeaux (FR); and Monique Vallee, Bordeaux (FR)
Assigned to AELIS FARMA, Bordeaux (FR); INSERM (Institut National de la Santé et de la Recherche Médicale), Paris (FR); and UNIVERSITE DE BORDEAUX, Bordeaux (FR)
Filed by AELIS FARMA, Bordeaux (FR); INSERM (Institut National de la Santé et de la Recherche Médicale), Paris (FR); and UNIVERSITE DE BORDEAUX, Bordeaux (FR)
Filed on Sep. 15, 2022, as Appl. No. 17/945,339.
Application 17/945,339 is a continuation of application No. 16/968,237, granted, now 11,484,537, previously published as PCT/EP2019/054217, filed on Feb. 20, 2019.
Claims priority of application No. 18305177 (EP), filed on Feb. 20, 2018.
Prior Publication US 2023/0226076 A1, Jul. 20, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/57 (2006.01); A61P 25/30 (2006.01)
CPC A61K 31/57 (2013.01) [A61P 25/30 (2018.01)] 24 Claims
 
1. A method for treating a Cannabinoids-Related Disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to Formula (I):

OG Complex Work Unit Chemistry
wherein the compound is administered to the subject at a dose between 10 g to 10 mg.